Purpose: The role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma (mRCC) is reviewed. Conclusion: The tyrosine kinase inhibitors sorafenib and sunitinib offer ...

which is comparing the drug to mainstay GIST treatment sunitinib. Deciphera has said that it expects Qinlock’s peak sales to reach $350 million to $400 million in the US alone, if it gets ...

Panelists discuss how the new tracing agent (Zr-DFO-girentuximab or 2050) works by binding to carbonic anhydrase IX, an enzyme expressed on the surface of most clear cell renal cancers, coupled with ...